Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 Congress

뉴스 본문을 불러오고 있어요.

Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 Congress | 웨이프 WAPE

Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 Congress

기사 요약

관련 종목

댓글 —